Clinical activity, immune and molecular correlates of nivolumab vs. nivolumab plus bevacizumab vs nivolumab plus ipilimumab in metastatic renal cell carcinoma

被引：5
|
作者：
Gao, Jianjun
Karam, Jose A.
Wood, Christopher G.
Matin, Surena
Ahrar, Kamran
Jonasch, Eric
Tannir, Nizar
Campell, Matthew
Ng, Chaan S.
Slack, Rebecca S.
Rao, Priya
Allison, James P.
Blando, Jorge M.
Vence, Luis M.
Basu, Sreyashi
Zhao, Hao
Chen, Tenghui
Chen, Hong
Sharma, Padmanee
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-CT083
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT083
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab plus axitinib vs. ipilimumab plus nivolumab
    Shah, Neil J.
    Sura, Sneha D.
    Shinde, Reshma
    Shi, Junxin
    Singhal, Puneet
    Perini, Rodolfo F.
    Motzer, Robert J.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (11) : 459.e1 - 459.e8
  • [2] Clinical outocomes of nivolumab plus ipilimumab in metastatic renal cell carinoma
    Kato, Taigo
    Fujita, Kazutoshi
    Nagahara, Akira
    Nakata, Wataru
    Matsuzaki, Kyousuke
    Hatano, Koji
    Kawashima, Atsunari
    Takada, Shingo
    Nishimura, Kensaku
    Tsujihata, Masao
    Takao, Tetsuya
    Nakai, Yasutomo
    Nakayama, Masashi
    Nishimura, Kazuo
    Uemura, Motohide
    Uemura, Hirotsugu
    Nonomura, Norio
    ANNALS OF ONCOLOGY, 2023, 34 : S1412 - S1412
  • [3] Clinical Activity of Ipilimumab Plus Nivolumab in Patients With Metastatic Non- Clear Cell Renal Cell Carcinoma
    Gupta, Ruby
    Ornstein, Moshe Chaim
    Li, Hong
    Allman, Kimberly D.
    Wood, Laura S.
    Gilligan, Timothy
    Garcia, Jorge A.
    Von Merveldt, Dendra
    Hammers, Hans J.
    Rini, Brian I.
    CLINICAL GENITOURINARY CANCER, 2020, 18 (06) : 429 - 435
  • [4] Nivolumab plus ipilimumab in advanced renal-cell carcinoma
    Gunjur, Ashray
    LANCET ONCOLOGY, 2018, 19 (05): : E232 - E232
  • [5] Head-to-head effectiveness and safety of pembrolizumab plus axitinib vs. nivolumab plus ipilimumab in metastatic renal cell carcinoma in the United States.
    Aran, Dvir
    Granot-Hershkovitz, Einat
    Amar-Farkash, Shlomit
    Rosenberg-Katz, Keren
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
    Choueiri, Toni K.
    Powles, Thomas
    Albiges, Laurence
    Burotto, Mauricio
    Szczylik, Cezary
    Zurawski, Bogdan
    Ruiz, Eduardo Yanez
    Maruzzo, Marco
    Zaizar, Alberto Suarez
    Fein, Luis E.
    Schutz, Fabio A.
    Heng, Daniel Y. C.
    Wang, Fong
    Mataveli, Fabio
    Chang, Yu-Lin
    van Kooten Losio, Maximiliano
    Suarez, Cristina
    Motzer, Robert J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (19): : 1767 - 1778
  • [7] Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
    Gervaso, Lorenzo
    Fazio, Nicola
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (05): : 476 - 477
  • [8] UNISON: Nivolumab then ipilimumab plus nivolumab in advanced nonclear cell renal cell carcinoma (ANZUP 1602)
    Gedye, Craig
    Pook, David William
    Krieger, Laurence Eliot Miles
    Harris, Carole A.
    Goh, Jeffrey C.
    Kichenadasse, Ganessan
    Gurney, Howard
    Underhill, Craig
    Parnis, Francis
    Joshua, Anthony M.
    Ferguson, Thomas
    Roncolato, Felicia
    Harrison, Michelle L.
    Morris, Michelle Frances
    Begbie, Stephen
    Hovey, Elizabeth J.
    George, Mathew
    Prithviraj, Prashanth
    Liow, Elizabeth Chien Hern
    Davis, Ian D.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [9] Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma
    Numakura, Kazuyuki
    Sekine, Yuya
    Hatakeyama, Shingo
    Muto, Yumina
    Sobu, Ryuta
    Kobayashi, Mizuki
    Sasagawa, Hajime
    Kashima, Soki
    Yamamto, Ryohei
    Nara, Taketoshi
    Akashi, Hideo
    Tabata, Ryuji
    Sato, Satoshi
    Saito, Mitsuru
    Narita, Shintaro
    Ohyama, Chikara
    Habuchi, Tomonori
    CANCER MEDICINE, 2023, 12 (16): : 16837 - 16845
  • [10] A Multicentre Retrospective Study of Nivolumab Plus Ipilimumab for Untreated Metastatic Renal Cell Carcinoma
    Kato, Renpei
    Kojima, Takahiro
    Sazuka, Tomokazu
    Yamamoto, Hayato
    Fukuda, Shohei
    Yamana, Kazutoshi
    Sugino, Yusuke
    Hamamoto, Shuzo
    Nakaigawa, Noboru
    Kabu, Koki
    Murakami, Hiroshi
    Obara, Wataru
    ANTICANCER RESEARCH, 2021, 41 (12) : 6199 - 6209
12345